|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Asker & Baerum Hospital |
|---|---|
| Information provided by: | Asker & Baerum Hospital |
| ClinicalTrials.gov Identifier: | NCT00353704 |
Purpose
The purpose of this study is to determine whether the use of oral pregabalin 150 mg as premedication reduces the amount and degree of postoperative pain.
Furthermore is the purpose of this study to determine whether the use of oral pregabalin 150 mg as premedication reduces anxiety prior to anaesthesia in these patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Intervertebral Disk Displacement Disk Prolapse |
Drug: pregabalin |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | Analgetic and Anxiolytic Effect of Preoperative Pregabalin in Patients Undergoing Surgery of the Vertebral Columna |
| Estimated Enrollment: | 80 |
| Study Start Date: | November 2005 |
| Estimated Study Completion Date: | September 2008 |
| Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
The mechanism of development of postoperative pain is complex. Central and peripheral sensitization are playing an important role and this can lead to postoperative hypersensitization. Several studies have shown, that gabapentin can be effective to reduce sensitization and postoperative pain. Pregabalin (S-aminomethyl-5-methylhexaninacid) is a further development of gabapentin. Pregabalin has a fewer side-effects compared with gabapentin.
The purpose of this study is to compare the analgetic and anxiolytic effect of pregabalin and placebo used as premedication.
The hypothesis is that a single-dose pregabalin (150 mg p.o.) gives significant better anxiolysis and analgesia than placebo.
The study is including patients undergoing surgery of the vertebral columna.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Ulrich J Spreng, Dr. med. | 47-6780-9400 | ulrich.spreng@sabhf.no |
| Contact: Vegard Dahl, Dr. med. | 47-9780-9400 | vegard.dahl@sabhf.no |
| Norway | |
| Asker and Baerum Hospital | Recruiting |
| Rud, Norway, 1309 | |
| Contact: Ulrich J Spreng, Dr. med. 47-6780-9400 ulrich.spreng@sabhf.no | |
| Principal Investigator: | Ulrich J Spreng, Dr. med. | Asker and Baerum Hospital, Norway |
| Study Director: | Vegard Dahl, Dr. med. | Asker and Baerum Hospital, Norway |
More Information
| Responsible Party: | Asker and Baerum Hospital ( Ulrich Johannes Spreng ) |
| Study ID Numbers: | 2005-003229-20 |
| Study First Received: | July 17, 2006 |
| Last Updated: | May 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00353704 History of Changes |
| Health Authority: | Norway: Norwegian Medicines Agency |
|
Intervertebral disk displacement laminectomy disk prolapse pregabalin |
|
Spinal Diseases Pathological Conditions, Anatomical Tranquilizing Agents Psychotropic Drugs Pregabalin Central Nervous System Depressants Prolapse |
Bone Diseases Musculoskeletal Diseases Anti-Anxiety Agents Analgesics Peripheral Nervous System Agents Intervertebral Disk Displacement Anticonvulsants |
|
Spinal Diseases Pathological Conditions, Anatomical Tranquilizing Agents Physiological Effects of Drugs Psychotropic Drugs Pregabalin Central Nervous System Depressants Prolapse Bone Diseases Pharmacologic Actions |
Musculoskeletal Diseases Sensory System Agents Therapeutic Uses Anti-Anxiety Agents Peripheral Nervous System Agents Analgesics Intervertebral Disk Displacement Central Nervous System Agents Anticonvulsants |